Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon.

BACKGROUND: Diabetes is a major cause of morbidity and mortality in both industrialized and developing countries. In Africa, there are little data on the prevalence and immunological features of patients with autoimmune endocrine diseases. AIM OF THE STUDY: The present hospital-based study was carried out to evaluate disease-associated autoantibodies in both type 1 diabetes and thyrotoxicosis attending the Central Hospital of Yaoundee in Cameroon. PATIENTS AND METHODS: Samples were collected from a total of 101 subjects, 47 of whom clinically had established type 1 diabetes (mean age 30.1 years +/- 7.6, mean disease duration 3.3 years), 18 had thyrotoxicosis (mean age 32.7 years +/- 7.6, mean disease duration 6.3 years +/- 2.8) and 36 normal subjects (mean age 26 years +/- 4.5). All subjects were tested for diabetes-associated glutamic acid decarboxylase (GAD) and tyrosine phosphatase (IA2) autoantibodies using antigen-specific radioimmunoassay as well as thyroiditis-associated thyroglobulin (Tg) and thyroid peroxidase (TPO) autoantibodies using commercially available kits. RESULTS: Of 47 patients with type 1 diabetes, 16 (34%) had GAD autoantibodies (Abs), 3 (6.4%) had IA2 Abs, and 2 (4.3%) had TPO Abs. Of 18 patients with thyrotoxicosis 4 (22.2%) had GAD Abs, 5 (27.8%) showed IA2 Abs, while 8 patients (44.4%) were TPO Abs positive. No patients in either group had Tg Abs. Among normal subjects, 2 (5.6%) showed GAD Abs, and one of these was also IA2 Abs positive, but none had thyroid autoantibodies. CONCLUSION: Adult-onset type 1 diabetic patients some years post-diagnosis from central Africa show GAD, IA2 or TPO Abs; and surprisingly, patients with thyrotoxicosis had a similar frequency of diabetes-associated autoantibodies. We conclude that, despite a different genetic and environmental background to European populations, islet cell autoimmunity is common in autoimmune endocrine patients in central Africa.

A hospital survey of the clinical features of diabetes in Congo.

The occurrence of diabetes mellitus is increasing throughout the world, both in industrialised nations and in developing countries. While this disease is not a leading cause of death in developing country populations, it must nevertheless be considered for its social and economic impact. This study examines the clinical and epidemiological situation of diabetes mellitus in the city of Kinshasa, Democratic Republic of Congo, as based on data from two city hospitals: Saint Joseph's Hospital (SJH) and the Centre Hospitalier Monkole (CHM), two urban health facilities typical of those developing countries. The results show that diabetes is a real public health problem in Congo. Average blood glucose levels were above 300 mg/dl in 44.4% of patients at SJH and 41.5% at CHM, and hypertension (> or = 140/90 mmHg) was reported in 35.8% of patients at SJH and 20% at CHM. The management of diabetes and, in particular, its complications is suffering because of some cultural influences but mainly economic ones. In fact, incidence of disease complications is closely linked to the financial status of patients and facilities. SJH, which serves mainly the low-income community, has a greater incidence of severe diabetes-associated complications than CHM, which treats patients with a higher mean income level. SJH hospitalised patients had a 24.7% incidence of diabetic foot with 3 amputations as compared to only a 10% incidence and no amputations for CHM hospitalised patients. At SJH, 17.3% of patients died during the study, while at CHM none died. Overall, differences in the prevalence of complications between SJH and CHM patients were found not to be significant. For the large majority of Congo population, education on diabetes is not available, and due to the failure of the national health system, access to treatment is impossible. Furthermore, because most diabetic people in Congo go untreated, the mortality rate for the disease is high. Congo would greatly benefit from a national diabetes program in order to give all diabetic patients in Congo access to good and consistent medical care.